AstraZeneca reports disappointing Phase 3 data for lung cancer ADC

IvelinRadkov AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said that a Phase 3 study of their antibody drug conjugate, or ADC, datopotamab deruxtecan did not show it was able to significantly extend lives versus the chemotherapy drug docetaxel. While the study's results for overall survival favored the drug, also known as Dato-DXd, they did not reach statistical significance, according to a statement . The data did show, however, a 2.

3 month improvement for Dato-DXd patients with non-squamous non-small cell lung cancer, or NSCLC, with overall survival of 14.6 months, compared with 12.3 months for patients given docetaxel.



In patients with squamous NSCLC, no overall survival improvement was observed. Shares of AstraZeneca closed 3% lower on Monday following the news. More on AstraZeneca, Daiichi Sankyo, etc.

Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Merck, Daiichi post mid-stage data for novel lung cancer drug UK regulators find no link between certain GLP-1 drugs, suicidal thoughts.